"That's my view. They'll cut preemptively in June. That is to say Wednesday," says the Grant's Interest Rate Observer newsletter editor.Economyread more
The Fed is not likely to make a move on interest rates when it meets this week, but it should clear the way for a rate cut later in the summer.Market Insiderread more
Ross played down the prospect of an agreement being reached at the G-20 meeting in Osaka on June 28-29.Paris Airshowread more
Boeing is scrambling to restore confidence in the 737 Max from regulators, customers and the flying public.Paris Airshowread more
Google CEO Sundar Pichai said in a CNN interview that while the company will work to remove as much harmful content as possible, the company can't remove 100% of it.Technologyread more
The chipmaker crush could persist and investors should be selective, but Nvidia looks like a clear buy, one market watcher says.Trading Nationread more
In a rare downgrade for the stock, Imperial Capital lowered its rating for Disney to in-line from outperform and maintained its target price of $147.Investingread more
Atlassian is releasing a document that's meant to simplify the negotiation of terms for acquisitions. That way the buyer and seller can focus on more important topics, like...Technologyread more
The pizza chain's robo delivery program could add to store owners' options during peak times.Restaurantsread more
GM CEO Mary Barra promised the automaker would launch 20 models of electric cars by 2023, beginning early this year. That plan may stall. A slowdown in China, a ratcheting up...Evolveread more
Amazon has held preliminary talks with makers of generic drugs about its potential entry into the pharmacy space, according to people familiar with the discussions.
The conversations, including with generics giants Mylan and Sandoz, a unit of Novartis, have been high-level, and the nature of Amazon's plans isn't yet clear, said the people, who asked not to be named because the discussions aren't public.
Shares of Mylan were up nearly 2.5 percent in after-hours trading.
Health care investment bank Leerink confirmed in a note to investors on Thursday that Sandoz' Peter Goldschmidt at a recent biopharma event "met and discussed with Amazon its plans for getting into the U.S. healthcare market." But it was not made clear whether Amazon will enter as a drug wholesaler, meaning business-to-business, or sell generic medications as a retailer.
Sandoz also said it does not expect Amazon to have a "major impact" on its business.
One of the people said the conversations are about Amazon taking a role in drug purchasing, potentially disrupting a space now dominated by distributors McKesson, AmerisourceBergen and Cardinal Health. Generics manufacturers are eager to establish a relationship with Amazon as part of 2018 business plans, the person said.
Stocks of drug distributors and others in the pharmaceutical supply chain, such as pharmacies and pharmacy benefits managers, have been pressured by the specter of Amazon entering the space.
Some in the industry have doubted the tech giant will make the decision to compete in pharmacy; at the Forbes Healthcare Summit Wednesday, Walgreens Boots Alliance CEO Stefano Pessina suggested the regulatory hurdles may be too high.
"I believe that they will not come in an industry so complicated as our industry," Pessina said. "I believe in the end they will use their technology in a different way."
It's a topic of intense speculation on Wall Street and in the pharmaceutical industry. Many drug company executives, including the CEOs of Pfizer and Allergan, were asked about the prospect of working with Amazon on their most recent quarterly earnings conference calls. They responded enthusiastically but said no formal discussions were taking place.
Novartis, Mylan and Amazon declined to comment.